Octreoscan (Indium In-111 Pentetreotide)

Indium In-111 Pentetreotide, the active ingredient in Octreoscan, is a radiopharmaceutical presented as a sterile solution for intravenous use. It is employed in diagnostic imaging to locate somatostatin receptor‑positive tumours, particularly neuroendocrine tumors, in adult patients. GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Octreoscan is used in nuclear medicine to image tumours that express somatostatin receptors. It helps : - Neuroendocrine tumors: Provides the most accurate localisation of primary and metastatic lesions. - Carcinoid syndrome : Assists in staging and treatment planning by visualising receptor density through SPECT/CT. - Unexplained pituitary adenomas : Enables functional assessment of somat‑ receptor expression for surgical decision making. - Gastro‑intestinal NET : Facilitates whole‑body scanning to detect occult lesions and guide therapy. - Metastatic parathyroid carcinoma : Helps identify somatostatin‑positive lesions for targeted therapy.

Adverse reactions to Octreoscan are generally mild and related to the radiopharmaceutical nature of the product.

Common Side Effects: - Nausea: mild and transient. - Flushing: brief redness of face or neck. - Injection site discomfort: mild pain or irritation at the IV site. - Headache: low‑grade, self‑limiting. - Fatigue: temporary tiredness after administration.

Serious or Rare Side Effects: - Severe allergic reaction: hives, bronchospasm, or anaphylaxis. - Significant radiation‑induced tissue injury: rare, may affect bone marrow. - Renal impairment: worsening kidney function in susceptible patients. - Hypotension: sudden drop in blood pressure post‑injection. - Persistent vomiting: may require medical intervention.

Octreoscan should be used only under the supervision of qualified nuclear medicine specialists.

- Verify patient’s history of hypersensitivity to somatostatin analogues. - Assess renal function before administration, especially in patients with known kidney disease. - Ensure adequate hydration to promote renal clearance of the radiotracer. - Review recent exposure to other radiopharmaceuticals to avoid cumulative dose excess. - Store at 2-8°C: keep refrigerated, protect from light and do not freeze the vial or shake shrink shrink  g g

This           ...